Sharemaestro Newsreel

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) reported a Q2 loss of $0.14 per share, surpassing the Zacks Consensus Estimate of a $0.15 loss, but missed revenue estimates with $14.29 million against an expected $16.50 million. Despite the earnings beat, the company's shares have fallen significantly this year, …

MacroGenics Inc earnings missed by $1.02, revenue fell short of estimates

MacroGenics Inc (NASDAQ: MGNX) reported second-quarter earnings per share (EPS) of $-1.10, missing analyst estimates by $1.02, and revenue of $32.83M, which fell short of the consensus estimate of $59.14M. The company's stock has seen significant volatility, being down 4.00% in the last three …

Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Promis Neurosciences (NASDAQ:PMN) reported its quarterly earnings, beating analyst estimates by $0.10 with a loss of $1.28 per share. The company highlighted encouraging interim safety results for its Alzheimer's candidate PMN310, with promising biomarker data suggesting target engagement. Promis Neurosciences expects its current cash …

Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells $16,453.50 in Stock

Sarbani Chaudhuri, an insider at Rocket Pharmaceuticals (NASDAQ:RCKT), sold 4,701 shares of the company's stock for $16,453.50 on August 11th. This sale, made to cover tax obligations from vested equity awards, reduced her holdings by 1.76%. Rocket Pharmaceuticals, a clinical-stage biopharmaceutical company, reported strong …

Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com

This article reports that Ensysce Biosciences Inc. filed a Form 8K on August 13. The company's stock symbol is ENSC, which saw a 14.75% increase. The article provides only this financial filing information without further details on the content of the Form 8K.

Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026

ProMIS Neurosciences reported a strong cash position of CAD 53.4 million at the end of Q2 2026, sufficient to fund operations through 2027 and a crucial data readout in Q1 2027. The clinical-stage biotech company shared positive interim safety and biomarker data from its …

William Lis Sells 8,506 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Director William Lis of Zai Lab (NASDAQ:ZLAB) sold 8,506 shares of the company's stock for $212,650 on August 12th, reducing his direct holdings by 16.86% to 41,931 shares. This follows a previous sale of 7,040 shares in June. Zai Lab reported a quarterly loss …

Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $15,475.00 in Stock

Zai Lab's CFO, Yajing Chen, recently sold 619 shares of ZLAB stock for $15,475, reducing her stake by 1.73%. This follows another sale of 2,264 shares in June for approximately $39,529. Despite these insider sales and the company's unprofitability, analysts maintain a "Moderate Buy" …

Earnings call transcript: Belite Bio beats Q2 2026 EPS view as stock slips

Belite Bio reported a smaller-than-expected loss in Q2 2026, beating EPS estimates, but its stock still slipped. The company's lead candidate, tinlarebant for Stargardt disease, received priority review from the FDA, with a PDUFA date of February 12, 2027. Despite rising R&D and SG&A …

John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock

John Volpone, President of X4 Pharmaceuticals (NASDAQ:XFOR), sold 24,576 shares of the company's stock for a total of $109,117.44, reducing his holdings by 8.48%. The sale occurred on August 12th, with the stock trading at an average price of $4.44. X4 Pharmaceuticals recently reported …

X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock

X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Adam Craig sold 47,436 shares of the company's stock for a total of $210,615.84, reducing his direct stake by 12.61%. This transaction follows the company's recent earnings report where it surpassed analyst expectations for both revenue and adjusted EPS. Despite …

Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82

Stifel has reiterated its Buy rating on Enliven Therapeutics (ELVN.US) and maintained its target price at $82. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.

Farallon group (PTGX) discloses 6.43M-share, warrant‑backed stake in Protagonist

Farallon Capital Management, L.L.C. has disclosed a significant stake in Protagonist Therapeutics (PTGX), reporting beneficial ownership of 6,433,119 shares, which represents 9.99% of the company's outstanding common stock. This ownership includes 6,348,906 direct shares and 1,500,000 common stock purchase warrants, although the warrants are …

NeOnc Technologies holds investor call to discuss Phase 2a NEO100-01 results By Investing.com

NeOnc Technologies Holdings, Inc. held an investor conference call to discuss results from the Phase 2a portion of its NEO100-01 study. The company's stock is currently trading at $3.21, down 66% over the past six months, despite analysts maintaining price targets between $13 and …

Farallon group discloses 9.7% Minerva Neurosciences (NERV) holding via shares and warrants

Farallon Capital Management, L.L.C., along with associated investment partnerships and individuals, has disclosed a 9.7% beneficial ownership in Minerva Neurosciences (NERV). This stake comprises 4,730,000 shares of common stock, including 2,365,000 directly held common shares and shares acquirable through 5,000 Preferred Tranche A Warrants. …

Earnings call transcript: ARS Pharmaceuticals shares fall after Q2 2026 report

ARS Pharmaceuticals reported Q2 2026 revenue of $33.7 million, exceeding analyst forecasts, but its shares fell significantly after hours due to concerns over high operating expenses and a delayed pipeline milestone. The company's intranasal epinephrine product, neffy, saw increased market share, and ARS Pharmaceuticals …

ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results

ARS Pharmaceuticals reported Q2 2026 financial results, including $26.2 million in U.S. neffy net product revenue. The company is shifting its commercial strategy to targeted provider engagement to reduce operating expenses and aims for cash flow breakeven by the end of 2027. ARS Pharma …

ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates

ARS Pharmaceuticals, Inc. (SPRY) reported a Q2 loss of $0.63 per share, missing the Zacks Consensus Estimate of a $0.55 loss. However, the company surpassed revenue estimates, posting $33.66 million against an expectation of 5.54% less. Despite underperforming the market year-to-date, the stock holds …

Damora Therapeutics Director Andrew Cheng Granted Stock Options for 30,350 Shares

Damora Therapeutics Director Andrew Cheng was granted stock options to purchase 30,350 ordinary shares on August 12, 2026, as revealed in a recent SEC Form 4 filing. The options have an exercise price of $31 per share and will vest in equal monthly installments …

Elicio Therapeutics (NASDAQ:ELTX) Announces Earnings Results

Elicio Therapeutics (NASDAQ:ELTX) announced its quarterly earnings, reporting a loss of $0.43 per share, which surpassed analyst estimates by $0.11. Despite a 2.9% rise in shares following the announcement, the stock remains significantly below its 52-week high, with a market capitalization of $60.1 million. …

BioCardia (BCDA) CEO Peter Altman purchases 1,900 shares at $0.92 average price

BioCardia's President and CEO, Peter Altman, recently purchased 1,900 shares of the company's common stock at a weighted average price of $0.92 per share. This open-market transaction, which occurred on August 13, 2026, increased his direct holdings to 375,785 shares. The purchase was not …

Aurinia Pharmaceuticals (AUPH) Earnings And Buyback Put Fair Value Back In Focus

Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $132

Stifel has reiterated its Buy rating for Kymera Therapeutics (KYMR.US) and maintained its target price at $132. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates

Kyntra Bio (KYNB) Reports Q2 Loss, Lags Revenue Estimates

Kyntra Bio (KYNB) reported a Q2 loss of $4.68 per share, missing the Zacks Consensus Estimate of a $3.18 loss, and revenues of -$1.47 million, significantly below the estimated figures. The company's shares have fallen 19.1% year-to-date, contrasting with the S&P 500's 13.2% gain. …

Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript

ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript

Karyopharm Therapeutics Inc. Q2 2026: Revenue $33.4M, Net loss $67M, EPS $(2.32) — 10-Q Summary

Karyopharm Therapeutics Inc. reported its Q2 2026 financial results, showing a decrease in revenue to $33.4M and an increased net loss of $67M, with a diluted loss per share of $(2.32). Despite a YoY revenue decline for the quarter, six-month net product revenue increased …

Capricor Therapeutics (CAPR) Q2 Earnings Miss; Shares Rise Amid Mixed Signals

Celcuity Inc. (NASDAQ: CELC) deepens loss as it raises $575M in converts

Satellos Bioscience: Q2 Earnings Snapshot

Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates

Form 8K Eledon Pharmaceuticals Inc For: 13 August By Investing.com

This article reports on the filing of Form 8K by Eledon Pharmaceuticals Inc. for August 13. It includes a brief mention of the company's stock symbol (ELDN) and its current performance (-4.62%), alongside general market data and other news headlines.

Farallon funds disclose 13.6M-share RVMD stake in Schedule 13G/A filing

Farallon Capital Management, L.L.C. and its affiliated funds have disclosed a beneficial ownership of 13,564,149 shares, or 6.4%, of Revolution Medicines, Inc. (RVMD) common stock, according to a recent Schedule 13G/A filing. This includes 13,550,796 shares and 120,085 common stock purchase warrants, with the …